Hartmut Derendorf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hartmut Derendorf has a total of 442 co-authors. Here are the top co-authors by number of shared publications:
- Sherwin Kenneth B. Sy
School of Medicine and Pharmacy Ocean University of China Qingdao China
19 shared publications Stephan Schmidt
Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
11 shared publications- Ravi Shankar Prasad Singh
Pfizer Inc Cambridge Massachusetts USA
10 shared publications Yichao Yu
University of Florida
9 shared publicationsJatinder Kaur Mukker
Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
7 shared publications- Daniel Gonzalez
Division of Clinical Pharmacology, Department of Medicine, Duke University School of Medicine, Durham, USA
6 shared publications
Latest Publications
- 15 June 2022
- Published by Springer Nature
- p. 601-613
Kinetics of Drug Action: A PKPD Approach
- 8 April 2022
- Published by Springer Nature
- p. 135-164
Basic Principles of Biopharmaceutics and Pharmacokinetics During Spaceflight
- 8 April 2022
- Published by Springer Nature
- p. 135-164
Basic Principles of Biopharmaceutics and Pharmacokinetics During Spaceflight
- 30 October 2021
- Published by Springer Nature
- p. 1-13
Kinetics of Drug Action: A PKPD Approach
- 1 September 2020
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 59 (9) , 1063
Roger W. Jelliffe, MD (1929-2020)
- 1 September 2020
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 59 (9) , 1063
Roger W. Jelliffe, MD (1929-2020)
- 1 June 2020
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 55 (6) , 106007
Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin
- 1 June 2020
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 55 (6) , 106007
Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin
- 1 December 2019
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 4 (4) , 240-254
Pharmacokinetic and Pharmacodynamic Characterization of Tetrahydrocannabinol-Induced Cannabinoid Dependence After Chronic Passive Cannabis Smoke Exposure in Rats
Introduction: Cannabis is the most widely used illicit drug in the US, and cannabis use among young adults continues to rise. Previous studies have shown that chronic administration of delta 9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis, induces dependence in animal models. Because smoking is the most frequent route of THC self-administration, it is critical to investigate the effects of cannabis smoke inhalation. The goal of the current study was to develop a rat model to characterize the pharmacokinetics (PKs) of THC after cannabis smoke inhalation, and to determine if chronic cannabis smoke inhalation leads to the development of cannabis dependence. Materials and Methods: For the PK study, male Wistar rats were administered THC intravenously (1 mg/kg) or exposed to smoke from 5 or 10 sequentially smoked cannabis cigarettes (5.3% THC) in an automated smoking machine. Plasma samples were collected from 10 min to 10 hours post smoke exposure (or intravenous administration) and analyzed using liquid chromatography–mass spectrometry to characterize the PK of THC. A three-compartment PK model was used to characterize the PKs. In a separate study, three groups of male Wistar rats were trained in an intracranial self-stimulation (ICSS) procedure, and exposed to smoke from burning 5 or 10 cannabis cigarettes (or clean air control conditions), 5 days/week for 4 weeks. Discussion and Conclusions: Across exposure days, the change from baseline in ICSS thresholds for cannabis smoke-exposed groups was significantly lower and response latencies were significantly faster in the cannabis smoke-exposed groups compared to controls, suggesting that chronic cannabis smoke exposure has rewarding properties. Acute administration of the CB1 receptor antagonist rimonabant (0.3, 1.0, 3.0 mg/kg) induced a dose-dependent increase in ICSS thresholds in the smoke-exposed rats, suggestive of dependence and withdrawal. Finally, an effect compartment PK-pharmacodynamic model was used to describe the relationship between THC concentrations and changes in ICSS thresholds after cannabis smoke exposure.
- 1 December 2019
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 4 (4) , 240-254
Pharmacokinetic and Pharmacodynamic Characterization of Tetrahydrocannabinol-Induced Cannabinoid Dependence After Chronic Passive Cannabis Smoke Exposure in Rats
Introduction: Cannabis is the most widely used illicit drug in the US, and cannabis use among young adults continues to rise. Previous studies have shown that chronic administration of delta 9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis, induces dependence in animal models. Because smoking is the most frequent route of THC self-administration, it is critical to investigate the effects of cannabis smoke inhalation. The goal of the current study was to develop a rat model to characterize the pharmacokinetics (PKs) of THC after cannabis smoke inhalation, and to determine if chronic cannabis smoke inhalation leads to the development of cannabis dependence. Materials and Methods: For the PK study, male Wistar rats were administered THC intravenously (1 mg/kg) or exposed to smoke from 5 or 10 sequentially smoked cannabis cigarettes (5.3% THC) in an automated smoking machine. Plasma samples were collected from 10 min to 10 hours post smoke exposure (or intravenous administration) and analyzed using liquid chromatography–mass spectrometry to characterize the PK of THC. A three-compartment PK model was used to characterize the PKs. In a separate study, three groups of male Wistar rats were trained in an intracranial self-stimulation (ICSS) procedure, and exposed to smoke from burning 5 or 10 cannabis cigarettes (or clean air control conditions), 5 days/week for 4 weeks. Discussion and Conclusions: Across exposure days, the change from baseline in ICSS thresholds for cannabis smoke-exposed groups was significantly lower and response latencies were significantly faster in the cannabis smoke-exposed groups compared to controls, suggesting that chronic cannabis smoke exposure has rewarding properties. Acute administration of the CB1 receptor antagonist rimonabant (0.3, 1.0, 3.0 mg/kg) induced a dose-dependent increase in ICSS thresholds in the smoke-exposed rats, suggestive of dependence and withdrawal. Finally, an effect compartment PK-pharmacodynamic model was used to describe the relationship between THC concentrations and changes in ICSS thresholds after cannabis smoke exposure.
- 1 July 2019
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 25 (7) , 904.e9-904.e16
A model-based analysis of pharmacokinetic–pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa
- 1 July 2019
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 25 (7) , 904.e9-904.e16
A model-based analysis of pharmacokinetic–pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa
- 12 April 2019
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 105 (6) , 1289-1291
Drug–Drug Interactions: Progress Over the Past Decade and Looking Ahead to the Future
- 12 April 2019
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 105 (6) , 1289-1291
Drug–Drug Interactions: Progress Over the Past Decade and Looking Ahead to the Future
- 1 March 2019
- Published by Elsevier in Drug Discovery Today
- Vol. 24 (3) , 845-857
Gastric-acid-mediated drug–drug interactions with direct-acting antiviral medications for hepatitis C virus infection: clinical relevance and mitigation strategies
- 1 March 2019
- Published by Elsevier in Drug Discovery Today
- Vol. 24 (3) , 845-857
Gastric-acid-mediated drug–drug interactions with direct-acting antiviral medications for hepatitis C virus infection: clinical relevance and mitigation strategies